APA (7th ed.) Citation

CA, Y., JM, H., K, V. B., R, R., FM, I., A, H., . . . R, M. (2022). Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience. Journal of immunotherapy (Hagerstown, Md. : 1997), 45(5), 254. https://doi.org/10.1097/CJI.0000000000000416

Chicago Style (17th ed.) Citation

CA, Yuen, et al. "Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement And/or HIV: A Multicenter Experience." Journal of Immunotherapy (Hagerstown, Md. : 1997) 45, no. 5 (2022): 254. https://doi.org/10.1097/CJI.0000000000000416.

MLA (9th ed.) Citation

CA, Yuen, et al. "Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement And/or HIV: A Multicenter Experience." Journal of Immunotherapy (Hagerstown, Md. : 1997), vol. 45, no. 5, 2022, p. 254, https://doi.org/10.1097/CJI.0000000000000416.